$CAPR
CAPRICOR THERAPEUTICS, INC.

2019 Q1 Form 10-K Financial Statement

#000114420419016787 Filed on March 29, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $230.5K $1.671M $480.0K
YoY Change -42.38% -37.32% -47.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $980.0K $4.930M $1.240M
YoY Change -29.5% 3.57% 7.83%
% of Gross Profit
Research & Development $1.811M $12.07M $2.520M
YoY Change -32.83% 12.08% -5.62%
% of Gross Profit
Depreciation & Amortization $43.30K $157.7K $30.00K
YoY Change 27.11% 9.35% -25.0%
% of Gross Profit
Operating Expenses $2.788M $17.00M $3.750M
YoY Change -31.78% 9.46% -1.83%
Operating Profit -$2.557M -$15.33M
YoY Change -30.63% 19.16%
Interest Expense $40.00K $0.00 -$70.00K
YoY Change -100.0% -30.0%
% of Operating Profit
Other Income/Expense, Net $136.0K
YoY Change -99.11%
Pretax Income -$2.520M -$15.19M $12.31M
YoY Change -31.34% -725.1% -372.35%
Income Tax
% Of Pretax Income
Net Earnings -$2.519M -$15.19M $12.31M
YoY Change -31.38% -724.78% -372.35%
Net Earnings / Revenue -1092.97% -908.91% 2564.58%
Basic Earnings Per Share
Diluted Earnings Per Share -$766.0K -$0.52 $3.062M
COMMON SHARES
Basic Shares Outstanding 33.66M 29.41M 25.71M shares
Diluted Shares Outstanding 29.41M

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.170M $7.260M $14.12M
YoY Change -45.54% -48.58% -12.78%
Cash & Equivalents $7.170M $4.260M $6.140M
Short-Term Investments $0.00 $3.000M $7.985M
Other Short-Term Assets $620.0K $1.010M $1.240M
YoY Change -45.61% -18.55% -26.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.904M $8.470M $15.71M
YoY Change -45.9% -46.09% -13.23%
LONG-TERM ASSETS
Property, Plant & Equipment $541.7K $570.0K $372.1K
YoY Change 0.32% 54.05% -14.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $130.0K $150.0K $100.0K
YoY Change -18.75% 50.0% 66.67%
Total Long-Term Assets $713.5K $780.0K $561.1K
YoY Change -8.53% 39.29% -12.19%
TOTAL ASSETS
Total Short-Term Assets $7.904M $8.470M $15.71M
Total Long-Term Assets $713.5K $780.0K $561.1K
Total Assets $8.618M $9.250M $16.27M
YoY Change -44.01% -43.15% -13.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M $1.260M $1.670M
YoY Change 1.35% -24.55% -52.69%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.501M $1.260M $1.671M
YoY Change 1.42% -24.55% -65.87%
LONG-TERM LIABILITIES
Long-Term Debt $3.380M $3.380M $3.380M
YoY Change 0.0% 0.0% -80.13%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $3.376M $3.380M $3.376M
YoY Change -0.11% 0.0% -81.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.501M $1.260M $1.671M
Total Long-Term Liabilities $3.376M $3.380M $3.376M
Total Liabilities $4.877M $4.630M $5.047M
YoY Change 0.56% -8.32% -77.82%
SHAREHOLDERS EQUITY
Retained Earnings -$69.26M -$51.55M
YoY Change 25.42% -4.5%
Common Stock $73.00M $62.76M
YoY Change 260879.45% 25.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.740M $4.620M $11.23M
YoY Change
Total Liabilities & Shareholders Equity $8.618M $9.250M $16.27M
YoY Change -44.01% -43.15% -13.19%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$2.519M -$15.19M $12.31M
YoY Change -31.38% -724.78% -372.35%
Depreciation, Depletion And Amortization $43.30K $157.7K $30.00K
YoY Change 27.11% 9.35% -25.0%
Cash From Operating Activities -$1.608M -$13.86M -$2.670M
YoY Change -52.96% -2.59% -23.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $316.5K $0.00
YoY Change -100.0% 883.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.980M $4.990M -$2.990M
YoY Change 49.0% -0.4% -71.5%
Cash From Investing Activities $2.985M $4.672M -$2.990M
YoY Change 64.75% -6.22% -71.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.433M $6.714M
YoY Change -39.61% -39.36%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.433M 6.853M 3.030M
YoY Change -42.96% -40.82%
NET CHANGE
Cash From Operating Activities -1.608M -13.86M -2.670M
Cash From Investing Activities 2.985M 4.672M -2.990M
Cash From Financing Activities 1.433M 6.853M 3.030M
Net Change In Cash 2.810M -2.337M -2.630M
YoY Change 210.0% -200.28% -81.29%
FREE CASH FLOW
Cash From Operating Activities -$1.608M -$13.86M -$2.670M
Capital Expenditures $0.00 $316.5K $0.00
Free Cash Flow -$1.608M -$14.18M -$2.670M
YoY Change -55.39% -0.59% -20.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Assets Current
AssetsCurrent
15712676
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
49772
CY2017Q4 us-gaap Other Assets
OtherAssets
95969
CY2018Q4 us-gaap Assets
Assets
9247065
CY2017Q4 us-gaap Assets
Assets
16273789
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1148853
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1496251
CY2018Q4 us-gaap Liabilities
Liabilities
4631478
CY2017Q4 us-gaap Liabilities
Liabilities
5046934
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
93048
CY2018Q4 us-gaap Other Assets
OtherAssets
151788
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2997150
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7984800
CY2018Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
204868
CY2017Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
344575
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
724184
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
501164
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8471299
CY2018Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
106366
CY2017Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
174424
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1255219
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1670675
CY2018Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
3376259
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1725590
CY2017Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
3376259
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3376259
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3376259
CY2018 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
135991
CY2017 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
38494
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017 us-gaap Interest Expense
InterestExpense
398807
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135991
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15293820
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15190322
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2439519
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6714324
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
31388
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
26271
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
71310720
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
62736783
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12393
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11620
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66738914
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51547819
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9247065
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16273789
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1671356
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2666340
CY2018 us-gaap Revenues
Revenues
1671356
CY2017 us-gaap Revenues
Revenues
2666340
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12066800
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10766095
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4931642
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4762642
CY2018 us-gaap Operating Expenses
OperatingExpenses
16998442
CY2017 us-gaap Operating Expenses
OperatingExpenses
15528737
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-15327086
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-12862397
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
773
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139140
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-15191095
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4615587
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-4003154
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11073152
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1710698
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8096
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6640
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
11226855
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-15191095
CY2017 us-gaap Net Income Loss
NetIncomeLoss
2431423
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
157652
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144174
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1725590
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1710698
CY2018 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-139707
CY2017 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
121240
CY2018 capr Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
223020
CY2017 capr Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
158272
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1542073
CY2018 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
55819
CY2017 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
34543
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-347398
CY2018 capr Increase Decrease In Accounts Payable And Accrued Expenses Related Party
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty
-68058
CY2017 capr Increase Decrease In Accounts Payable And Accrued Expenses Related Party
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty
-314793
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
398807
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1367186
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13862441
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14230879
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
18011577
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
18986194
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
23000000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24000000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
316486
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32185
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4671937
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4981621
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6714324
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11073152
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
500000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139140
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6640
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6853464
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11579792
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2337040
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2330534
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4551603
CY2018 us-gaap Interest Paid Net
InterestPaidNet
0
CY2017 us-gaap Interest Paid Net
InterestPaidNet
0
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2018Q4 capr Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
7300000
CY2017Q4 capr Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
14100000
CY2018Q4 capr Amount Available Under Grant Awards
AmountAvailableUnderGrantAwards
700000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4259266
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6140135
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
285831
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
742002
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4545097
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6882137
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
300000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
700000
CY2018 us-gaap Depreciation
Depreciation
114376
CY2017 us-gaap Depreciation
Depreciation
94968
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1030232
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
713746
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
456026
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
341650
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
574206
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
372096
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
43276
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49206
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
43277
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4330
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2165
CY2018Q1 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
4190
CY2018Q3 capr Leases Monthly Payments For Additional Twelve Months
LeasesMonthlyPaymentsForAdditionalTwelveMonths
19756
CY2018Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P1Y
CY2018 us-gaap Payments For Royalties
PaymentsForRoyalties
20000
CY2018 capr Written Notice Period
WrittenNoticePeriod
P90D
CY2016Q3 capr Upfront Payment
UpfrontPayment
2500
CY2017Q4 capr Reimbursed Expenses To Be Paid
ReimbursedExpensesToBePaid
50000
CY2018 capr Payments For Reimbursement For Research And Development Expenses Incurred Related Party
PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty
400000
CY2017 capr Payments For Reimbursement For Research And Development Expenses Incurred Related Party
PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty
900000
CY2018 capr Compensation Receivable In Connection To Services To Be Provided
CompensationReceivableInConnectionToServicesToBeProvided
2100000
CY2018 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
700000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
209910
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
166634
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
2997150
CY2017Q4 us-gaap Marketable Securities
MarketableSecurities
7984800
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
12500
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
16666
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31387729
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26270491
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q2 capr Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Additional Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalGrantsInPeriod
4166
CY2018Q2 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
54162
CY2018Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
56497
CY2017Q4 capr Amount Authorized In Plans After Merger
AmountAuthorizedInPlansAfterMerger
4149710
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.31
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.83
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1669093
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1710698
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
521678
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
117849
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7400000
CY2016Q4 capr Disbursement Amount Under Grant Award
DisbursementAmountUnderGrantAward
3100000
CY2017Q4 capr Disbursement Amount Under Grant Award
DisbursementAmountUnderGrantAward
300000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31387729
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26270491
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 capr Loan Payable Forgiven
LoanPayableForgiven
0
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.10
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29410973
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23193278
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29410973
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26788076
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
276259
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Use of Estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin: 0px 0px 0px 0.25in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the recoverability and fair value of intangible assets and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 capr Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
2.27
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1081716
CY2017Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
4.01
CY2018 capr Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
235643
CY2018 capr Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
2.27
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
846073
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29410973
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23193278
CY2018 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3594798
CY2017 us-gaap Interest Expense
InterestExpense
398807
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1081903
CY2016Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
4.01
CY2017 capr Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
187
CY2018Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
4.50
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
7013140
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
6027821
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1400000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
138292
CY2017 capr Written Notice Period
WrittenNoticePeriod
P90Y
CY2018 capr Cost For Clinical Trial Services
CostForClinicalTrialServices
42600
CY2017 capr Loan Payable Forgiven
LoanPayableForgiven
15654133
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
29043739
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
138292
CY2018 us-gaap Interest Expense
InterestExpense
0
CY2017 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
184000
CY2018Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
76100000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2018 dei Trading Symbol
TradingSymbol
CAPR
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33661346
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-016787-index-headers.html Edgar Link pending
0001144204-19-016787-index.html Edgar Link pending
0001144204-19-016787.txt Edgar Link pending
0001144204-19-016787-xbrl.zip Edgar Link pending
capr-20181231.xml Edgar Link completed
capr-20181231.xsd Edgar Link pending
capr-20181231_cal.xml Edgar Link unprocessable
capr-20181231_def.xml Edgar Link unprocessable
capr-20181231_lab.xml Edgar Link unprocessable
capr-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv513994_10k.htm Edgar Link pending
tv513994_ex21-1.htm Edgar Link pending
tv513994_ex23-1.htm Edgar Link pending
tv513994_ex31-1.htm Edgar Link pending
tv513994_ex31-2.htm Edgar Link pending
tv513994_ex32-1.htm Edgar Link pending
tv513994_ex32-2.htm Edgar Link pending